Covid-19: Pfizer Boosters Now Authorized for Teens
FDA moves to widen booster coverage as Omicron looms The FDA kicked of the new year with three...
Read More
BreakingMed
Covid-19: Clotting Disorders Pause Roll-Out of Adenovirus Vaccines
Regulators in U.S. and Europe link vaccines to CVST and thrombocytopenia Several setbacks hampered...
Read More
Breakthrough Covid Shows Reduced Risk for Long Haul Symptoms
Vaccinated cases 50% less likely to have long Covid vs unvaccinated in U.K. study Individuals who...
Read More
Giving Covid-19, Flu Vaccines Together Is Safe, Study Finds
CDC, WHO now say there’s no need to separate vaccines Can the Covid-19 vaccine and the flu...
Read More
Plasma cfDNA Testing in Hospital May Speed Tx in Suspected Advanced NSCLC
Pilot study finds in-hospital testing slashes result wait time In hospitalized patients, plasma...
Read More
Melflufen Achieves Response in Relapsed/Refractory Multiple Myeloma
Benefit observed in patients who progressed after multiple therapies This article, which was...
Read More
Add-on Bevacizumab Fails to Improve Osimertinib Benefit in NSCLC
Moving the PFS needle may require new agents Researchers documented their attempts to improve PFS...
Read More
Precision Medicine: It’s All About Biomarker Testing
Guidelines recommend biomarker testing, but is it done? Next-generation sequencing (NGS) may help...
Read More
Adding Metformin to Chemo Only Makes Things Worse for NSCLC Patients
OCOG-ALMERA and NRG0LU001 trial results—no survival benefit from adding metformin to...
Read More
Multiple Myeloma: Health-Related QoL Maintained with Selinexor Tx for Most Patients
Response seen in 1 in 4 patients in difficult to treat population Health-related quality of life...
Read More
RET-Positive NSCLC: Treatment Options for a Rare, But Targetable, Rearrangement
Pralsetinib in particular shows potency against uncommon oncogenic driver While treatment options...
Read More
Empagliflozin for HFrEF: A Win-Win with Improved CV, Renal Outcomes Independent of SBP
Better outcomes with no increased risk of hypotension It could be said that 2021 was the year of...
Read More
Death Risk High in CLL Patients Infected with Covid-19
Risk is equally high for patients in ’watch and wait’ mode after prior treatment The...
Read More
Multiple Myeloma: Study Finds Benefit for Adding Dexamethasone to Anti-CD38 Agents
Overall response increased, but no survival benefit This article, originally published April 15,...
Read More
ACC: Investigational MRA Reduces New Onset AFib in CKD/T2D
Analysis finds 30% relative risk reduction This article, published May 17, 2021, took a look at...
Read More
EMPRISE: Interim Results Support Real-World Efficacy, Safety of Empagliflozin
Three interim analyses showed superiority of empagliflozin in reducing risks of all-cause...
Read More
Triplet Regimen Steps Up as Potential First-Line CLL Therapy
Phase II trial supports efficacy, safety of oral acalabrutinib-based therapy A triple-therapy drug...
Read More
What Drives the Clinical Benefits Seen with SGLT2 Inhibitors?
Volume, volume, volume may be the answer SGLT2 inhibition again took the spotlight in 2021, this...
Read More
ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Read More
ECTRIMS: Cortical Lesions at MS Diagnosis Predict Secondary Progressive Disease
Imaging with MRI identifies active SPMS Identifying markers for progression to secondary MS could...
Read More